Cargando…

Hematologic complications of immune checkpoint inhibitors

Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food and Drug Administration for the treatment of 14 solid tumors and 2 hematologic malignancies. These medicati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroll, Michael H., Rojas-Hernandez, Cristhiam, Yee, Cassian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Immunotherapies for Nonmalignant Hematologic Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227102/ https://www.ncbi.nlm.nih.gov/pubmed/34610113 http://dx.doi.org/10.1182/blood.2020009016

Ejemplares similares

Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia
por: Wang, Peipei, et al.
Publicado: (2023)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

An insight into the invasion of breast ductal carcinoma in situ based on clinical, pathological and hematological data
por: Liu, Yanbiao, et al.
Publicado: (2022)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

An Overview of Complete Blood Count Sample Rejection Rates in a Clinical Hematology Laboratory Due to Various Preanalytical Errors
por: Noor, Tayyab, et al.
Publicado: (2023)

Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy
por: Andreescu, Mihaela
Publicado: (2023)

Two Older Hematological Malignancy Patients for Whom Nutrition Rehabilitation Was Effective Against Global Leadership Initiative on Malnutrition-Defined Malnutrition and Sarcopenia
por: Matsunaga, Takuya, et al.
Publicado: (2023)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Frequency of Specific and Non-specific Inhibitors in Haemophilia A Patients
por: Ashfaq, Javeria, et al.
Publicado: (2022)

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
por: Ma, Yuxiang, et al.
Publicado: (2021)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Aortic Valve Replacement in Severe Factor V Deficiency and Inhibitor: Diagnostic and Management Challenges
por: Bello, Alexa, et al.
Publicado: (2019)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Immune Thrombocytopenic Purpura in an Adult Male: A Case Report
por: Thapa Chhetri, Suchit, et al.
Publicado: (2023)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
por: Nishiyama-Fujita, Yuriko, et al.
Publicado: (2022)

Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature
por: Chartier, Alexander R, et al.
Publicado: (2020)

Reticulated Platelet Count as a Diagnostic Tool in Immune Thrombocytopenia (ITP)
por: Butt, Aqsa Javed, et al.
Publicado: (2023)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

Cooccurrence of CD10-Positive and CD10-Negative Mantle Cell Lymphoma Complicated With Central Nervous System Involvement Solely by CD10-Positive Population
por: Fukushima, Noriyasu, et al.
Publicado: (2022)

Severe hyperferremia and hyperferritinemia in a dog with precursor‐directed immune‐mediated anemia
por: Zersen, Kristin M., et al.
Publicado: (2022)

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
por: de Joode, Karlijn, et al.
Publicado: (2023)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
por: de Kouchkovsky, Ivan, et al.
Publicado: (2021)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors
por: Gandhe, Nalinikumari, et al.
Publicado: (2021)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
por: Yang, Xu, et al.
Publicado: (2021)

Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
por: Magahis, Patrick T, et al.
Publicado: (2023)

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
por: Maslov, Diana V, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ghfnvf9n9m96bvtj45cub2h9l4